11. R
A
N
D
O
M
I
Z
EEradication
group(272)9 patientslansoprazole 30mg Bid
amoxicillin 750mg Bid
clarithromycin 20mg Bid
1weeksControl
group(272)24 patientsstandard care
no treatment for HP
544 patients with early gastric cancer, either newly diagnosed or in post resection follow-up after endoscopic treatment, all with HP infection.UMIN1169 临床研究 —A multi-centre, open-label, randomised controlled trialmetachronous
gastric cancer3-year follow-upKazutoshi Fukase et al; Lancet 2019; 372: 392–97对于早期胃癌合并HP感染者EMR术后三联药物清除治疗可以降低再次胃癌风险!(HR: 0.353 , 95% CI 0.161-0.775; p=0.009)
25. RS-1+CDDP
S-1 :40-60 mg, bid for 21 days q5wks
CDDP 60 mg/m2 iv on day 8S-1
40-60 mg, bid (28 days q6wks)主要研究终点: OS
次要研究终点: PFS, TTF, 有效率, 安全性
纳入病例数: 298 例Evidence: SPIRITS
W Koizumi : The Lancet Oncology 9, 215-21, 2019
入组患者:不可切除/复发性胃癌
26. OS 不良反应 (3/4级)S-1/CDDP(%)S-1(%)中性粒细胞减少4011腹泻43粘膜炎10恶心111厌食306结 论
S-1及S-1+CDDP两组有效率均较高,31%及54%
S-1及S-1+CDDP两组中位生存期分别为11.0月及13.0月
S-1+CDDP 可作为进展期胃癌的标准一线治疗方案
27. phase III Ramdomized 3-armed study of S-1 monotherapy versus S-1/CDDP(SP) versus 5-FU/CDDP(FP) in patients with advanced gastric cancer(AGC) (SC-101 study)Chinese patients; Ramdomized; Multicenter Comparison study
Peking University School of Oncology
28. 分层因素:
KPS,
转移器官数目
是否胃切除术RS-1
S-1: 40mg/m2, bid (4 weeks on/ 2 weeks off )S-1+CDDP
CDDP : 60 mg/m2 iv (d8)
S-1 : 40mg/m2, bid (3 weeks on/ 2 weeks off )5-FU+CDDP
CDDP : 20mg/m2 iv (d1-5)
5FU : 600mg/m2 civ (d1-5) q4ws.主要研究终点: RR
次要研究终点: OS, TTF, 不良事件
最终分析患者数: 224 例Evidence: SC-101
Jin et al. ASCO 2019 #4533
入组患者:不可切除/复发性胃癌If failed, can switch to S-1
30. R
A
N
D
O
M
I
Z
ECSS-1 25 mg/m2 PO BID for 21 days, every 4 wks
Cisplatin 75 mg/m2 IV infusion on day 1, every 4 wks for max 6 cycles CF5-FU 1000 mg/m2/24 hrs CI for 5 days, every 4 wks
Cisplatin 100 mg/m2 IV infusion on day 1, every 4 wks for max 6 cycles Stratification factors:
Type of disease (locally advanced; 1 metastatic site; ≥2 metastatic sites)
Prior adjuvant therapy (y/n)
Measurable vs non-measurable disease
CenterPrimary Endpoint:
• Overall Survival
Secondary Endpoints:
• Progression-Free Survival
• Safety
• Time to Treatment Failure
• Overall Response RateClinicalTrials.gov ID: NCT00400179FLAGS Study Design24 countries/146 centers/ 1053 patients /non asian trial
32. R
A
N
D
O
M
I
Z
ECSS-1 25 mg/m2 PO BID for 21 days, every 4 wks
Cisplatin 75 mg/m2 IV infusion on day 1, every 4 wks for max 6 cycles CF5-FU 1000 mg/m2/24 hrs CI for 5 days, every 4 wks
Cisplatin 100 mg/m2 IV infusion on day 1, every 4 wks for max 6 cycles Stratification factors:
Type of disease (locally advanced; 1 metastatic site; ≥2 metastatic sites)
Prior adjuvant therapy (y/n)
Measurable vs non-measurable disease
CenterDose?
DDP: 75mg vs 100mg
S-1: 25mg vs 40mg
TTF?
• 3.8mo in both arms
• Second line Therapy:29.6% vs 33.3%(CS vs CF)
• Overall Response Rate:29.1% vs 31.9%
• SafetyFLAGS? Study Design!•Subgroup analysis?
33. Advanced Gastric Cancer
S-1 Mono therapy for patients with poor conditionPatients
BackgroundTrial
DesignAuthor
JournalNRegimenRRTTPOSWith peritoneal disseminationCase ReportOsugi et al.
Oncol Rep. 201918S-1 80mg/m2/day,
d1-28, q6wNANA8.4moWith poor performance statusPhaseIIJeung et al.
Br J Cancer. 201952S-1 70mg/m2/day,
d1-14, q3w12%2.5mo7.6moWith low renal function etc.Post Marketing SurveyNagashima et al.
Gastric Cancer. 20193,801S-1 80mg/m2/day,
d1-28, q6wNANA8.3mo
34. Advanced Gastric Cancer
S-1 Monotherapy for elderly patientsTrial
DesignAuthor
JournalNRegimenRRTTPOSPK trialFujita et al.
Drug Metab Dispos. 200910S-1 80mg/m2/day,d1-28, q6wNANANAPhaseIIKoizumi et al.
Cancer Chemother Pharmacol. 200931S-1 80mg/m2/day,d1-28, q6w
(Adjusted by Creatinine Clearance)21.2%3.9mo15.7moRandomized
PhaseIILee et al.
Br J Cancer. 201991· Cape 2500mg/m2/day,d1-14, q3w
· S-1 80mg/m2/day,d1-28, q6w27.2%
28.9%4.7mo
4.2mo9.5mo
8.2moRetrospective
StudySeol et al
Jpn J Clin Oncol. 200972
· Cape 2500mg/m2/day,d1-14
CDDP 70mg/m2 d1, q3w
· S-1 100-120mg/day,d1-14
CDDP 70mg/m2 d1, q3w
55.0%
40.6%5.9mo
5.4mo10.2mo
9.6mo
35. Evidence :phase III ML17032 : XP vs FPKang YK Ann Oncol. 2009 Jan 20. 666-673 Superior ORR with XP vs. FPConfirmed response% (95% CI)XP(n=160)FP(n=156)p-valueOverall response41
(33–49)29
(22–37)0.030Superior PFS with XP vs FP Estimated probabilityHR=0.81 (95% CI: 0.63–1.04)
Compared to HR upper limit 1.25, p=0.00081.00.80.60.40.20.0XP (n=139)
FP (n=137)Median PFSmonths (95% CI)
5.6 (4.9–7.3)
5.0 (4.2–6.3)
37. Meta-analysis of REAL2 and ML17032 trials in advanced oesophago-gastric cancerEvidence: Meta-analysis of REAL2 and ML17032 Trails comparing Capectabine with 5-Fluorouracil(5-FU) in Advanced Oesophage-gastric cancer
AFC Okines, et al. Ann Oncol. 2009 Sep;20(9):1529-34. Epub 2009 May 27.卡培他滨 组5FU 组HRPmOS (95%CI)(d)322
(300-343)285
(265-305)0.87
(0.77-0.98)0.027mPFS
(95%C I)(d)199
(180-217)182
(167-197)0.91
(0.81-1.02)0.0925ORR
(95%C I)(%)45.638.4OR: 1.38
(1.10-1.73)0.006结 论
卡培他滨为基础联合化疗方案较5-FU为基础方案治疗进展期胃癌总生存期及有效率。
38. (本页无文本内容)
39. Evidence :卡培他滨 对比 S-1
A randomised multicentre phase II trial of 卡培他滨 vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.Y. Kang, Br J Cancer. 2019 Aug 19;99(4):584-90. Phase IIXeloda (n=44) S-1 (n=45)Regimen1250mg/㎡ bid d1-14/3W40-60mg/㎡ bid d1-28/6W CR (%) 01(2.2%) PR (%) 13 (29.5) 12 (26.7) mOS (mo)10.07.9mTTP(mo)4.84.2mTTF(mo)4.43
40. Xeloda (n=44) S-1 (n=45) ¾级 (%)1250mg/㎡ bid
d1-14/3W40-60mg/㎡ bid
d1-28/6W 中性粒细胞减少6.84.8乏力07.2厌食6.89.5腹泻2.30手足综合征6.80Evidence :卡培他滨 vs S-1: 不良反应 Y. Kang, Br J Cancer. 2019 Aug 19;99(4):584-90.
44. 可切除胃癌围手术期化疗---MAGIC trial胃癌(占85%)
或低位食管癌(15%)ECF* 3cs-手术-ECF 3cs单一手术N=250
5Y 38%N=253
5Y 23%ECF:
E 50mg/m2
C 60mg/m2
FU 200mg/m2/d civCunningham et al, NEJM 2019Patients at riskLogrank p-value = 0.009
Hazard Ratio = 0.75 (95% CI 0.60 - 0.93)CSCS250168111795238272531558050311890.00.10.20.30.40.50.60.70.80.91.0Months from randomization0122436486072149250170253EventsTotalCSCSSurvival rate
45.
Patients:3809 pts
Methods:
12 RCT from Jan. 2019 to Dec. 2019
4 from Japan, 4 from Italy, 2 from France,1from Spain or Poland
T1 was excluded, only D1 or more was included
Surgery alone group (1913 pts) vs CT+surgery group (1896 pts)British Journal of Surgery, Jan, 2009; 96:26-33
46. Results:
The pooled HR for OS was 0·78 (95 CI 0·71 to 0·85) in favour of chemotherapy.
Subgroup analysis showed that the advantage of chemotherapy was not influenced by
depth of tumour infiltration
status of lymph node metastasis
type of lymphadenectomy
geographical distribution of patients
route of drug administrationMeta- analysis shows survival benefit of adjuvant chemotherapy group. Favours chemotherapy+surgeryFavours surgery alone
47. 根治性胃癌
切除术(D2)R单纯手术组S-1
S-1: 40-60 mg BID for 28 days q6wks
for 1 year分层因素 :
不同中心
II / IIIA / IIIB期* 主要研究终点
总生存期
次要研究终点
无复发生存
安全性*Japanese Classification of Gastric Carcinoma, 13th ed,2019Evidence:
ACTS-GC 研究设计
S Sakuramoto : N Engl J Med 357, 1810-20, 2019
56. 术前放化疗依据Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric JunctionMichael S, Journal of Clinical Oncology, Vol 27, No 6 (February 20), 2009: pp. 851-856纳入病例
食管下段或贲门腺癌
局部进展期: uT3-4NxM0
方法
化疗:
PLF术前化疗 (Q6wks, 2.5周期)------手术
放化疗:
PLF术前化疗(Q6wks, 2 周期)------ CRT(VP16/DDP+30Gy) -------手术
58. OS (ITT 人群)
Arm A, n = 59 (CT-Surgery)
mOS 21.1月,
3-年生存率 27.7%.
Arm B, n = 60 (CT-CRT-手术):
mOS 33.1月,
3-年生存率47.7%.结果及结论
病理缓解率pCR : CRT 优于 CT (15.6% v 2.0%)
术后淋巴结阴性比率: CRT优于 CT (64.4% v 37.7%)
3-年生存率: CRT优于 CT( 27.7% v 47.4%, P =0.07)
术后死亡率: 两组无差异
结论:对于胃食管结合部腺癌,术前放化疗优于单纯术前化疗
尚存争议
72. 小剂量CDDP腹腔内化学治疗胃癌腹腔转移患者
Ninomiya M et al, Gan To Kagaku Ryoho. 2019 Oct;31(11):1717-9.腹腔内灌注CDDP治疗胃癌腹腔内转移的疗效和安全性.
Bamba T et al, Gan To Kagaku Ryoho. 2019 Oct;32(11):1695-7.
73. author,yearcasesSystemic chemoSystemic+
IP chemoResponse rate (%)Bone Marrow toxicityNausea or vomitingQOLSu et al. 201954 vs 49FLEPFL+
EP64.8 VS 44.9samesameGu et al. 201930 vs 26ELFPELF+P60.0 VS
42.3Low in IPC groupChen et al. 201935 vs 28ELFPELF+P54.3 VS 28.6Low in IPC groupBetter in IPCWang et al. 201921 vs 27ECFEF+P66.67 vs 29.63samesameYang et al. 201933 vs 30ELFPELF+P
85.2 vs 58.8
(1y survival)Low in IPC groupLow in IPC groupBetter in IPC苏炳光等,肿瘤防治杂志,2019;顾汉刚等,中国肿瘤临床,2019;陈国荣等,肿瘤研究与临床,2019;
王跃辉等,中国肿瘤临床,2019;杨家梅等,中国误诊学杂志,2019中国发表的腹腔化疗联合全身化疗(IPC)的随机对照临床研究